Objective: HIV is a cardiovascular disease (CVD) risk factor. However, CVD risk is often underestimated in HIV-infected women. C-reactive protein (CRP) may improve CVD prediction in this population. We examined the association of baseline plasma CRP with subclinical CVD in women with and without HIV.
Introduction
Persons living with HIV who are treated with antiretroviral therapy (ART) can expect to attain a near-normal life expectancy [1] ; however, they have an increased risk of age-related comorbidities, including cardiovascular disease (CVD) [2] . Compared with the general population, HIV-infected individuals have greater rates of myocardial infarctions (MIs) and ischemic strokes, especially at younger ages [3] [4] [5] [6] [7] . In addition, although the incidence of CVD is greater among men than women, the relative contribution of HIV to CVD risk may be greater among HIV-infected women than HIVinfected men: in observational studies, HIV-infected women had a two to three-fold increased risk of MI and stroke compared with their HIV-uninfected counterparts, whereas HIV-infected men had an approximately 1.5-fold increased risk [6] [7] [8] [9] . However, CVD risk prediction tools, including the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort equations, do not include HIV as a CVD risk factor, and underestimate CVD risk in HIV-infected individuals [10, 11] , particularly among women and minority populations [12] .
There is a clear need to improve CVD risk assessment in these populations. C-reactive protein (CRP) is an acute phase reactant associated with subclinical CVD progression and clinical CVD in the general population [13, 14] and is included in the ACC/AHA guidelines as an option to improve risk-stratification among intermediate-risk persons [10] . However, its association with both subclinical and hard clinical CVD outcomes in the HIV population is less clear [15, 16] , and data in HIVinfected women are particularly lacking. To determine the association of CRP with subclinical CVD prevalence and progression among HIV-infected women, we retrospectively analyzed data from the Women's Interagency HIV Study (WIHS) carotid ultrasound substudy, in which measures of subclinical CVD, including carotid intima -media thickness (CIMT) and carotid plaque formation, which are associated with subsequent clinical CVD events [17] , were obtained. We tested for differences in association by HIV serostatus.
Materials and methods
Study population WIHS is a multisite, longitudinal cohort of HIV-infected and at-risk HIV-uninfected women in the United States [18] . Study design has been described previously [18, 19] . Briefly, participants undergo semiannual detailed interviews, physical examinations, and specimen collections. In 2004, WIHS initiated a longitudinal carotid artery ultrasound substudy; all WIHS participants at all six clinical sites were eligible for enrollment in the substudy [20] . For this retrospective analysis, we included all substudy participants with at least two carotid artery ultrasound substudy visits who had high-sensitivity (hs) CRP measured at the baseline substudy visit. WIHS participants who HIV seroconverted during the followup period were excluded from the analysis (Fig. 1) . All participants provided informed consent, and the study was approved by each participating institution's Institutional Review Board.
Data collection
CIMT and focal carotid plaques were measured by highresolution B-mode ultrasonography according to previously published procedures [21] at a baseline substudy visit between 2004 and 2006, and at a final substudy visit between 2010 and 2013. All sites used a standardized protocol, and outcome measures were obtained at a centralized reading center (University of Southern California) [20, 22] . The coefficient of variation for repeated measures of CIMT in the WIHS cohort has been published previously [20] . Citrate plasma hsCRP was obtained at the baseline substudy visit on fasting samples obtained in duplicate and measured by a nephelometric immunoassay (Dade-Behring BN II) [23] . Demographic, clinical, and laboratory data were collected by standardized protocols at the WIHS core visit closest to the baseline substudy visit.
Outcome measures
Primary outcomes measures were baseline CIMT, presence of any baseline focal plaques, change in CIMT, and focal plaque progression. CIMT was measured at a 1-cm segment of the right common carotid artery far wall just distal to the carotid bifurcation. Focal plaque was defined as an area of focal intima-media thickness more than 1.5 mm in any of the six imaged segments: near and far walls of the common carotid artery, the carotid bifurcation, and the internal carotid artery [22] . Change in CIMT was defined as the difference between the final and baseline CIMT measurements. Focal plaque progression was defined as the number of new plaques formed in each participant between the baseline and final visits.
Measurement of covariates
HIV infection was determined by serologic testing using ELISA and confirmed with western blot assays. Plasma HIV RNA levels (viral load) were quantified using nucleic-acid-sequence-based amplification assays with a lower limit of quantification of 80 copies/ml (bioM erieux, Boxtel, North Carolina, USA), total peripheral CD4 þ T-cell counts were measured with standard flow cytometric methods. CD4 þ T-cell nadir was defined as the lowest CD4 þ T-cell count prior to ART initiation. ART use was defined as the use of three or more antiretroviral medications. History of clinical CVD was defined as a history of MI, angina, revascularization, transient ischemic attack, or stroke. Diabetes was defined as fasting glucose at least 126 mg/dl, glycated hemoglobin at least 6.5%, or self-reported antidiabetic medication use. Chronic hepatitis C virus (HCV) infection was defined as a positive enzyme immunoanalysis and detectable HCV RNA. Lipid levels were obtained following an 8-h fast. Estimated glomerular filtration rate (eGFR) was determined by the Chronic Kidney Disease Epidemiology Collaboration equation [24] . Age, race/ethnicity, crack/cocaine use, current smoking status, and antihypertensive and lipidlowering medication use were self-reported.
Statistical analysis
Baseline characteristics of HIV-infected and HIVuninfected participants were compared by chi-square for categorical variables, and Student's t tests or Wilcoxon rank-sum tests for continuous variables, as appropriate. For each outcome, hsCRP was analyzed as a categorical variable with a cutpoint of at least 3 mg/l [25] , and as a continuous (natural log-transformed) variable. As chronic HCV is associated with lower hsCRP levels [26] , we also assessed the difference in hsCRP by HIV serostatus after excluding all participants with chronic HCV.
Multivariable linear and logistic regression models were used to assess the association of baseline hsCRP with baseline CIMT, and with the presence of baseline focal plaques, respectively. Multivariable linear regression and Poisson regression models were used to assess the association of baseline hsCRP with change in CIMT, and with focal plaque progression, respectively. After checking for collinearity, models were adjusted for age, race/ethnicity, SBP, antihypertensive and lipid-lowering medication use, LDL cholesterol, diabetes, history of CVD, eGFR, current smoking status, crack/cocaine use, and HCV. For each model, we assessed the interaction between dichotomized hsCRP (above or below 3 mg/l) and HIV status; nonsignificant interaction terms were removed from the model. Separate analyses by HIV status were conducted, and models for HIV-infected individuals were also adjusted for CD4 þ cell count, CD4 þ nadir, HIV viral load, and ART use. Finally, we examined the association of baseline hsCRP with subclinical CVD progression outcomes among HIV-infected women with persistent virologic suppression defined as an HIV viral load less than 80 copies/ml at all substudy visits while on continuous ART. Consistent with prior studies [22] , we allowed for one virologic 'blip' if the viral load remained less than 500 copies/ml. We also performed the same analyses among HIV-infected women who did not have persistent virologic suppression.
Analyses were conducted using SAS v9.4 (SAS Institute, Cary, North Carolina, USA). Statistical significance was determined using a P value of less than 0.05.
Results
Baseline characteristics A total of 1870 WIHS participants participated in the carotid ultrasound study. Of these, 788 had more than one carotid ultrasound and baseline hsCRP. Five women were excluded for HIV seroconversion, so 783 (572 HIVinfected and 211 HIV-uninfected) women were included in this analysis (Fig. 1) . The median [interquartile range (IQR)] time between baseline and final carotid artery ultrasound was 6.6 (6.4-7.0) years. Baseline characteristics stratified by HIV status are shown in Table 1 . The median age at the first substudy visit was 41 years. A total of 62% of the women were black and 29% were Hispanic. HIV-infected women had lower baseline BMI, SBP, HDL cholesterol, and prevalence of diabetes, higher HCV prevalence, and similar LDL levels as HIV-uninfected women. Three percent of women in each group had a history of clinical CVD, and the average 10-year Framingham CVD risk [27] in both groups was 1%. More HIV-uninfected than HIV-infected women were current smokers and used crack/cocaine. Among HIVinfected participants, the median CD4 þ cell count was 452 cells/ml, 46% had HIV viral load less than 80 copies/ ml, and 62% were on ART. Median (IQR) baseline hsCRP was higher among HIV-uninfected women than HIV-infected women [3.2 (0.9-7.7) vs. 2.2 (0.8-5.3) mg/l, P ¼ 0.005], but baseline focal plaques and median CIMT were not different between groups. In women without chronic HCV, there was a trend toward higher median baseline hsCRP among HIV-uninfected women compared with HIV-infected women that was not statistically significant [3.4 (1.0-7.9) vs. 2.6 (1.2-5.6) mg/l, P ¼ 0.08)].
Association of high-sensitivity C-reactive protein with baseline subclinical cardiovascular disease The interaction between HIV status and dichotomized hsCRP was not statistically significantly associated with either baseline CIMT or baseline focal plaques (P ¼ 0.20 and 0.72, respectively). After multivariable adjustment, there was no association between dichotomized hsCRP and baseline CIMT among all women [estimated mean difference high vs. low hsCRP À3.5 mm (95% confidence interval (CI): À19.0 to 12.1)] (Fig. 2a) . High baseline hsCRP was positively associated with focal plaque prevalence among all women [adjusted odds ratio 1.31 (95% CI: 0.67-2.67)], but the association was not statistically significant (Fig. 2b) . Similar associations were observed when hsCRP was analyzed as a continuous variable (data not shown).
Association of high-sensitivity C-reactive protein with progression of subclinical cardiovascular disease There was no statistically significant association of an interaction of HIV status and dichotomized hsCRP with CIMT progression (P ¼ 0.67). After multivariable adjustment, dichotomized hsCRP was positively associated with CIMT progression among all women (estimated mean difference high vs. low hsCRP 11.4 mm (95% CI: À2.3 to 25.1), although this association was not statistically significant (Fig. 2c) (11) 65 (12) 15 (8) 
Discussion
In a well characterized cohort of HIV-infected and at-risk HIV-uninfected women with similar 10-year Framingham risk scores, we report that baseline plasma hsCRP levels at least 3 mg/l are positively associated with progression of focal carotid plaques among HIVuninfected, but not HIV-infected, women. We did not find any statistically significant association between hsCRP levels and baseline prevalence of subclinical CVD, nor did we find any statistically significant association between baseline hsCRP and CIMT progression, although there was a trend toward greater CIMT progression with high baseline hsCRP in both groups. Both groups had low Framingham CVD risk and similar subclinical CVD outcomes at baseline. Although HIV infected participants had lower SBP, BMI, and prevalence of diabetes, and higher HDL cholesterol than HIVuninfected participants, these differences were small and unlikely to be clinically significant. Rates of smoking in both groups was higher than the national average [28] and were even higher among HIV-uninfected participants.
Similarly, crack and/or cocaine use was higher among HIV-uninfected participants, although current crack/ cocaine use was low overall.
We also report higher baseline hsCRP levels in the HIV-uninfected group. This finding was somewhat unexpected as HIV infection has been shown to be positively associated with hsCRP elevation [29] . However, this association seems to be stronger in men than women [30, 31] , which may account for differences between our study and others that have included men. Furthermore, hsCRP levels increase with ART administration in men and women [23] . In our analysis, only 62% of HIV-infected women were on ART, which may contribute to the lower hsCRP in that group. This discrepancy also may be due in part to the higher rate of chronic HCV in the HIV-infected group. CRP is synthesized by hepatocytes, and prior data have shown that HCV infection is associated with lower plasma hsCRP [26, 32] . Indeed, when all HCV-infected participants were excluded from the analysis, the difference in hsCRP was no longer statistically significant. However, as HCV status was included in the multivariable models, this difference should not affect our overall conclusions. It is also possible that other causes of inflammation, including smoking status and crack/cocaine use, which were higher in the HIV-uninfected group, contributed to the higher baseline hsCRP in this population. Finally, HIV-infected participants had a higher rate of lipid-lowering medication use, although the overall use was low (6 vs. 3%). It is possible that more statin use among HIV-infected women contributed to the lower hsCRP in this group, but it is unlikely to be a major factor as the overall prevalence of statin use in both groups was very low.
The current study adds to a growing body of literature concerning CVD biomarkers in the HIV population. HsCRP is positively associated with CVD events in HIVinfected persons in most observational studies [16, 33, 34] . Its association with subclinical CVD measures in this Models are adjusted for age, race/ethnicity, SBP, antihypertensive and lipid-lowering medication use, LDL cholesterol, diabetes, history of cardiovascular disease, estimated glomerular filtration rate, current smoking status, crack/cocaine use, and hepatitis C virus. Models for HIV-infected also adjusted for CD4 R cell count, CD4 R nadir, HIV viral load, and antiretroviral therapy use. CIMT, carotid intima-media thickness; hsCRP, high-sensitivity C-reactive protein; LCL, lower confidence limit; MD, mean difference; OR, odds ratio; RR, rate ratio; UCL, upper confidence limit.
population is more variable [15] , possibly due to different mechanisms of atherogenesis, including the greater role of innate and adaptive immune activation in the setting of HIV infection [30, 35] . In our study, the lack of association between baseline hsCRP and subclinical CVD progression outcomes among HIV-infected women both with and without persistent virologic suppression, unlike in HIV-uninfected women, suggests there are factors beyond HIV viremia that contribute to subclinical CVD progression in HIV-infected women. Therefore, it is possible that hsCRP, which is positively associated with atherosclerosis and MI in the general population, may not be associated as strongly with these outcomes in persons living with HIV.
Our study has limitations. Its retrospective design limits our ability to control for all potential confounders. We used subclinical rather than clinical endpoints. Although carotid artery plaques and CIMT are correlated with CVD events in the general population [36] , their association with CVD in the HIV-infected population is unknown. Also, we examined only two measures of atherosclerosis at the carotid artery. Examination of other vessels and other measures of atherosclerosis, such as echogenicity and arterial stiffness, may yield different results. In addition, our cohort was composed of relatively young women with few CVD risk factors and limited clinical CVD. It is possible that the association of hsCRP with subclinical CVD progression would have become apparent with longer follow-up. In addition, as with any multivariable modeling, we were limited in the number of predictors that we could use without over-fitting our models and were unable to account for all possible covariates that might contribute to CVD risk including duration of HIV infection, duration of protease inhibitor therapy, and abacavir use [37] . Finally, our findings may not be generalizable to men. However, an important scientific strength of this study is the inclusion of women, especially those from racial and ethnic minorities, who have been historically underrepresented in both HIV and CVD clinical trials [38, 39] .
In conclusion, we report that hsCRP predicts focal carotid artery plaque progression in HIV-uninfected, but not HIV-infected, women. These findings suggest that hsCRP is not a reliable biomarker for CVD in women in the setting of HIV infection, which could be because the pathogenesis of subclinical CVD may be different in HIVinfected women. Further investigation of alternative CVD biomarkers and the pathogenesis of CVD in the setting of HIV infection is warranted.
